Akebia Ther (AKBA)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $131.67M
Last updated: Nov 17, 2026 at 11:04 AM ET
Akebia Ther (AKBA) Earnings: Report Dates and Results
Akebia Ther (AKBA) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Akebia Ther reported EPS of -$0.04, below the -$0.03 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
AKBA has an expected report date of Feb 24, 2027.
AKBA Earnings Call
The latest AKBA earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, AKBA beat 16, missed 23 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $36.90M, down 37.2% from $58.77M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.04 | -$0.03 | -$0.04 - -$0.02 | -33.33% | Miss | -2100.0% | 2 | 1 up, 0 down | Nov 5, 2026 | $36.90M |
| Jun 30, 2026 | -$0.02 | -$0.03 | -$0.03 - -$0.02 | +33.33% | Beat | -174.9% | 2 | 1 up, 0 down | Aug 5, 2026 | $49.13M |
| Mar 31, 2026 | -$0.03 | -$0.02 | -$0.02 - $0.01 | -50.00% | Miss | -250.0% | 2 | 0 up, 0 down | May 7, 2026 | $53.54M |
| Dec 31, 2025 | -$0.05 | -$0.03 | N/A | -66.67% | Miss | N/A | 2 | 0 up, 1 down | Feb 26, 2026 | $57.62M |
| Sep 30, 2025 | $0.00 | -$0.04 | N/A | +105.00% | Beat | N/A | 1 | N/A | Nov 10, 2025 | $58.77M |
| Jun 30, 2025 | $0.03 | -$0.02 | -$0.04 - -$0.01 | +233.50% | Beat | N/A | 2 | 0 up, 1 down | Aug 7, 2025 | $62.47M |
| Mar 31, 2025 | $0.02 | -$0.04 | -$0.04 - -$0.04 | +150.00% | Beat | N/A | 2 | 1 up, 1 down | May 8, 2025 | $57.34M |
| Dec 31, 2024 | -$0.10 | -$0.08 | -$0.11 - -$0.04 | -33.33% | Miss | -3225.0% | 2 | 0 up, 0 down | Mar 13, 2025 | $46.50M |
| Sep 30, 2024 | -$0.10 | -$0.05 | -$0.09 - -$0.03 | -100.00% | Miss | N/A | 3 | 0 up, 0 down | Nov 7, 2024 | $37.43M |
| Jun 30, 2024 | -$0.04 | -$0.05 | -$0.08 - -$0.03 | +20.00% | Beat | N/A | 3 | 0 up, 0 down | Aug 8, 2024 | $43.65M |
| Mar 31, 2024 | -$0.08 | -$0.09 | -$0.11 - -$0.05 | +11.11% | Beat | N/A | 3 | 0 up, 0 down | May 9, 2024 | $32.61M |
| Dec 31, 2023 | $0.00 | -$0.04 | -$0.06 - -$0.03 | +108.00% | Beat | N/A | 3 | 0 up, 0 down | Mar 14, 2024 | $56.20M |
| Sep 30, 2023 | -$0.08 | -$0.08 | -$0.10 - -$0.07 | 0.00% | In line | N/A | 2 | 0 up, 0 down | Nov 8, 2023 | $42.05M |
| Jun 30, 2023 | -$0.06 | -$0.02 | -$0.05 - $0.00 | -200.00% | Miss | -126.1% | 2 | 0 up, 0 down | Aug 25, 2023 | $56.38M |
| Mar 31, 2023 | -$0.14 | -$0.15 | -$0.16 - -$0.14 | +6.67% | Beat | N/A | 2 | 0 up, 0 down | May 8, 2023 | $40.01M |
| Dec 31, 2022 | -$0.04 | -$0.19 | -$0.27 - -$0.14 | +78.95% | Beat | N/A | 3 | 0 up, 0 down | Mar 9, 2023 | $117.41M |
| Sep 30, 2022 | -$0.29 | -$0.12 | -$0.22 - -$0.12 | -141.67% | Miss | N/A | 3 | 0 up, 0 down | Nov 3, 2022 | $48.71M |
| Jun 30, 2022 | $0.23 | -$0.33 | -$0.36 - -$0.26 | +169.70% | Beat | N/A | 4 | 0 up, 0 down | Aug 4, 2022 | $126.36M |
| Mar 31, 2022 | -$0.35 | -$0.29 | -$0.36 - -$0.22 | -20.69% | Miss | N/A | 6 | 0 up, 0 down | May 9, 2022 | N/A |
| Dec 31, 2021 | -$0.40 | -$0.33 | -$0.44 - -$0.25 | -21.21% | Miss | N/A | 7 | N/A | Mar 1, 2022 | $57.68M |
| Sep 30, 2021 | -$0.34 | -$0.29 | -$0.42 - -$0.27 | -17.24% | Miss | N/A | 6 | 1 up, 0 down | Nov 4, 2021 | $48.76M |
| Jun 30, 2021 | -$0.51 | -$0.31 | -$0.51 - -$0.16 | -64.52% | Miss | N/A | 8 | N/A | Aug 5, 2021 | $52.91M |
| Mar 31, 2021 | -$0.45 | -$0.36 | -$0.55 - $0.17 | -25.00% | Miss | N/A | 8 | N/A | May 10, 2021 | $52.30M |
| Dec 31, 2020 | -$0.60 | -$0.40 | -$0.51 - -$0.29 | -50.00% | Miss | N/A | 7 | N/A | Feb 25, 2021 | $56.04M |
| Sep 30, 2020 | -$0.42 | -$0.24 | -$0.33 - $0.20 | -75.00% | Miss | N/A | 8 | N/A | Nov 5, 2020 | $59.99M |
| Jun 30, 2020 | -$0.44 | -$0.47 | -$0.74 - -$0.32 | +6.38% | Beat | N/A | 8 | N/A | Aug 10, 2020 | $90.14M |
| Mar 31, 2020 | -$0.47 | -$0.60 | -$0.74 - -$0.48 | +21.67% | Beat | N/A | 8 | N/A | May 5, 2020 | $88.48M |
| Dec 31, 2019 | -$0.79 | -$0.47 | -$0.55 - -$0.26 | -68.09% | Miss | N/A | 8 | N/A | Mar 10, 2020 | $69.56M |
| Sep 30, 2019 | -$0.46 | -$0.41 | -$0.52 - -$0.31 | -12.20% | Miss | N/A | 7 | N/A | Nov 12, 2019 | $91.98M |
| Jun 30, 2019 | -$0.49 | -$0.35 | -$0.45 - -$0.14 | -40.00% | Miss | N/A | 7 | N/A | Aug 8, 2019 | $100.80M |
| Mar 31, 2019 | -$0.62 | -$0.40 | -$0.52 - -$0.25 | -55.00% | Miss | N/A | 8 | N/A | May 9, 2019 | $72.67M |
| Dec 31, 2018 | -$0.93 | -$0.38 | -$0.53 - $0.43 | -144.74% | Miss | -472.0% | 6 | N/A | Mar 26, 2019 | $59.85M |
| Sep 30, 2018 | -$0.46 | -$0.56 | -$1.13 - -$0.47 | +17.86% | Beat | N/A | 7 | N/A | Nov 8, 2018 | $53.17M |
| Jun 30, 2018 | -$0.60 | -$0.42 | -$0.83 - -$0.33 | -42.86% | Miss | N/A | 7 | N/A | Aug 8, 2018 | $48.79M |
| Mar 31, 2018 | -$0.48 | -$0.53 | -$0.99 - -$0.37 | +9.43% | Beat | N/A | 8 | N/A | May 9, 2018 | $45.93M |
| Dec 31, 2017 | $0.25 | -$0.35 | -$0.59 - $0.00 | +171.43% | Beat | N/A | 9 | N/A | Mar 12, 2018 | $90.56M |
| Sep 30, 2017 | -$0.49 | -$0.46 | -$0.79 - -$0.24 | -6.52% | Miss | N/A | 7 | N/A | Nov 8, 2017 | $41.28M |
| Jun 30, 2017 | -$0.53 | -$0.92 | -$1.24 - -$0.76 | +42.39% | Beat | N/A | 5 | N/A | Aug 8, 2017 | $28.52M |
| Mar 31, 2017 | -$1.15 | -$0.41 | N/A | -180.49% | Miss | N/A | N/A | N/A | May 9, 2017 | $20.86M |
| Dec 31, 2016 | -$0.99 | $0.77 | N/A | -228.57% | Miss | N/A | N/A | N/A | Mar 6, 2017 | $1.53M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.00, after -$0.32 the year before. It was -$3.60 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.00 | N/A |
| Dec 31, 2024 | -$0.32 | N/A |
| Dec 31, 2023 | -$0.28 | N/A |
| Dec 31, 2022 | -$0.45 | N/A |
| Dec 31, 2021 | -$1.70 | N/A |
| Dec 31, 2020 | -$1.93 | N/A |
| Dec 31, 2019 | -$2.36 | N/A |
| Dec 31, 2018 | -$2.47 | N/A |
| Dec 31, 2017 | -$1.92 | N/A |
| Dec 31, 2016 | -$3.60 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,300 words across 12 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,312 | 12 | |
| 2026Q1 | Mar 31, 2026 | 4,078 | 10 | |
| 2025Q4 | Dec 31, 2025 | 5,113 | 8 | |
| 2025Q3 | Sep 30, 2025 | 5,247 | 9 | |
| 2025Q2 | Jun 30, 2025 | 4,589 | 8 | |
| 2025Q1 | Mar 31, 2025 | 5,946 | 10 | |
| 2024Q4 | Dec 31, 2024 | 5,523 | 8 | |
| 2024Q3 | Sep 30, 2024 | 5,341 | 8 |
2026Q3 Earnings Call
Opening remarks
Mercedes Carrasco Senior Director, Investor Relations Thank you, and welcome to Akebia's third quarter 2026 financial results and business updates conference call. Please note that a press release was issued earlier today, Thursday, November 5th, detailing our third quarter 2026 financial results, and that release is available on the investor section of our website. For your convenience, a replay of today's call will also be available on our website after we conclude. Joining me for today's call, we have John Butler, Chief Executive Officer, and Erik Ostrowski, Chief Financial and Chief Business Officer. Dr. Steven Burke, our Chief Medical Officer, and Nicholas Grund, Chief Commercial Officer, are also available for questions. I'd like to remind everyone that this call includes forward-looking statements. Each forward-looking statement on this call is subject to risks and uncertainties that could cause actual results to differ materially from those described in these statements. Additional information describing these risks is included in the financial results press release that we issued on November 5th, as well as in the risks, factors, and management discussion and analysis section of our most recent annual and quarterly reports filed with the SEC. With that, I'd like to introduce our CEO, John Butler.
John Butler CEO Thanks, Mercedes. Good morning, everyone, and thank you for joining us today. Late last month, Akebia joined our peers at ASN Kidney Week in Denver. I left the event with two important takeaways. First, I heard tremendous excitement about the VOICE trial data that Dr. Block of USRC presented. We believe the data, which demonstrated a clear and compelling hospitalization outcomes benefit for vadadustat versus an ESA, dosed in a regimen that most dialysis providers have chosen to implement, will have dialysis organizations thinking differently about Vafseo, and over time has the potential to drive Vafseo to become standard of care. Second, the spotlight continues to shine on rare kidney disease therapeutic product development, and we're excited about the potential to show meaningful differentiation with our mid-stage pipeline assets across multiple rare kidney indications. We believe this would represent significant value for our shareholders. Now, with this backdrop, let me walk through Q3, starting with our commercial business. We are pleased with the pace at which we are adding patients from the mid-sized dialysis providers, including USRC, DCI, and IRC. Last quarter, the number of patients on Vafseo increased to about 11,500 patients on therapy, representing about 20% of patients treated for anemia within these three dialysis organizations. Also important, 25% of patients that had previously discontinued therapy have restarted. Even with this progress, I believe we have significant room to continue driving growth even within the mid-sized dialysis providers, but obviously and especially at the large dialysis organizations.
Frequently Asked Questions About AKBA
When is Akebia Ther's next earnings date?
Akebia Ther's next earnings report is expected for Feb 24, 2027.
Did AKBA beat earnings estimates last quarter?
No. Akebia Ther reported EPS of -$0.04 for the quarter ended Sep 30, 2026, below the -$0.03 estimate by 33.33%.
What EPS do analysts expect from AKBA next quarter?
The consensus EPS estimate for Akebia Ther for the quarter ending Dec 31, 2026 is -$0.04 from 8 analysts, with estimates from -$0.07 to -$0.01.
How often does AKBA beat earnings estimates?
Akebia Ther beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +42.31%.
AKBA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors